KN-62 是一种选择性的、可逆的钙调蛋白依赖性蛋白激酶 II (CaMK-II) 抑制剂,对大鼠脑 CaMK-II 的IC50值为 0.9 μM。KN-62 直接与 CaMK-II 酶的钙调蛋白结合位点结合。KN-62 是非竞争性的P2X7受体拮抗剂,IC50约为 15 nM。
生物活性 | KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with aKiof 0.9 μM for rat brain CaMK-II. KN-62 directly binds to thecalmodulinbinding site of CaMK-II. KN-62 displays noncompetitive antagonism atP2X7receptors in HEK293 cells, with anIC50value of approximately 15 nM. |
IC50& Target[1][2] | |
体外研究 (In Vitro) | KN-62 potently antagonizes ATP-stimulated Ba2+influx into fura-2 loaded human lymphocytes with an IC50of 12.7 nM and complete inhibition of the flux at a concentration of 500 nM[1]. KN-62 does not inhibit the activity of autophosphorylated Ca2+/CaM kinase II. KN-62 inhibits the Ca2+/calmodulin-dependent autophosphorylation of both alpha (50 kDa) and beta (60 kDa) subunits of Ca2+/CaM kinase II dose dependently in the presence or absence of exogenous substrate[2]. In human leukemic B lymphocytes, KN-62 reduces the rate of permeability increase to larger permeant cations, like ethidium, induced by Bz-ATP with an IC50of 13.1 nM[4].
|
体内研究 (In Vivo) | KN62 (5 mg/kg/day; ip; three times a week for 6 weeks) significantly reduces the liver metastatic tumor burden in five weeks old BALB/c athymic nude mice inoculated with TAMR-MCF-7 cells[3]. KN-62 (1 μg/site, i.c.v.) prevents the antidepressant-like behavior and antidepressant-like behaviors of ZnCl2(10 mg/kg, p.o.)[5].
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(138.53 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 1.3853 mL | 6.9267 mL | 13.8535 mL | 5 mM | 0.2771 mL | 1.3853 mL | 2.7707 mL | 10 mM | 0.1385 mL | 0.6927 mL | 1.3853 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.46 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.46 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|